Delphine Planas

This study examines how SARS-CoV-2 RBD antibodies differ in function, showing that neutralizing antibodies lose effectiveness against variants but retain effector functions, while non-neutralizers remain broadly reactive but less effective overall.

This study shows human coronavirus HKU1 replicates more efficiently at nasal temperature (33°C) than at body temperature (37°C), with differences in innate immune response and viral stability.

The paper shows that variant-specific spike conformational dynamics influence memory B cell recruitment and antibody responses during vaccination.

This paper develops a single domain antibody targeting ACE2 that protects against SARS-CoV-2 infection in mice when delivered intranasally.

The paper evaluates the neutralization activity of two new monoclonal antibodies against emerging SARS-CoV-2 variants and finds reduced efficacy against some sublineages.

The paper develops a Lymphoid Organ-Chip to evaluate mRNA vaccine boosting strategies by mimicking immune responses to SARS-CoV-2 Spike protein and comparing monovalent and bivalent vaccines.

This study shows metformin reduces HIV-1 virion release and increases antibody recognition of infected CD4+ T-cells by modulating BST2 and Bcl-2 expression in HIV-positive individuals on ART.

This study characterizes SARS-CoV-2 variants XBB and BA.2.86/JN.1, finding they show increased fitness and antibody evasion while maintaining antiviral sensitivity.

The paper assesses the neutralization of SARS-CoV-2 Omicron subvariants BA.2.86 and EG.5.1 by antibodies from prior infection or vaccination, finding comparable neutralization titres to XBB.1 and EG.5.1.

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.